Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)ReceivablesReceivables - NetShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ascendis Pharma A (ASND) Total Current Liabilities (2016 - 2025)

Historic Total Current Liabilities for Ascendis Pharma A (ASND) over the last 14 years, with Q3 2025 value amounting to $1.2 billion.

  • Ascendis Pharma A's Total Current Liabilities rose 2524.35% to $1.2 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.2 billion, marking a year-over-year increase of 2524.35%. This contributed to the annual value of $982.6 million for FY2024, which is 2399.87% up from last year.
  • As of Q3 2025, Ascendis Pharma A's Total Current Liabilities stood at $1.2 billion, which was up 2524.35% from $1.1 billion recorded in Q2 2025.
  • Ascendis Pharma A's 5-year Total Current Liabilities high stood at $1.2 billion for Q3 2025, and its period low was $84.7 million during Q2 2021.
  • In the last 5 years, Ascendis Pharma A's Total Current Liabilities had a median value of $212.9 million in 2023 and averaged $485.2 million.
  • As far as peak fluctuations go, Ascendis Pharma A's Total Current Liabilities surged by 256436.92% in 2021, and later surged by 517.28% in 2022.
  • Ascendis Pharma A's Total Current Liabilities (Quarter) stood at $100.0 million in 2021, then soared by 74.73% to $174.7 million in 2022, then skyrocketed by 353.5% to $792.4 million in 2023, then grew by 22.42% to $970.1 million in 2024, then rose by 18.88% to $1.2 billion in 2025.
  • Its Total Current Liabilities stands at $1.2 billion for Q3 2025, versus $1.1 billion for Q2 2025 and $931.5 million for Q1 2025.